%0 Journal Article
%T Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts
%A Maria T Baquero
%A Karen Lostritto
%A Mark D Gustavson
%A Kimberly A Bassi
%A Franck Appia
%A Robert L Camp
%A Annette M Molinaro
%A Lyndsay N Harris
%A David L Rimm
%J Breast Cancer Research
%D 2011
%I BioMed Central
%R 10.1186/bcr2937
%X MAP-tau expression was evaluated in the retrospective Yale University breast cancer cohort (n = 651) using tissue microarrays and also in the TAX 307 cohort, a clinical trial randomized for TAC versus FAC chemotherapy (n = 140), using conventional whole tissue sections. Expression was measured using the AQUA method for quantitative immunofluorescence. Scores were correlated with clinicopathologic variables, survival, and response to therapy.Assessment of the Yale cohort using Cox univariate analysis indicated an improved overall survival (OS) in tumors with a positive correlation between high MAP-tau expression and overall survival (OS) (HR = 0.691, 95% CI = 0.489-0.974; P = 0.004). Kaplan Meier analysis showed 10-year survival for 65% of patients with high MAP-tau expression compared to 52% with low expression (P = .006). In TAX 307, high expression was associated with significantly longer median time to tumor progression (TTP) regardless of treatment arm (33.0 versus 23.4 months, P = 0.010) with mean TTP of 31.2 months. Response rates did not differ by MAP-tau expression (P = 0.518) or by treatment arm (P = 0.584).Quantitative measurement of MAP-tau expression has prognostic value in both cohorts, with high expression associated with longer TTP and OS. Differences by treatment arm or response rate in low versus high MAP-tau groups were not observed, indicating that MAP-tau is not associated with response to taxanes and is not a useful predictive marker for taxane-based chemotherapy.Taxanes are microtubule stabilizing agents and potent cytotoxic compounds that have been recognized as highly effective chemotherapeutic agents [1,2]. However, varying degrees of benefit, with response rates ranging from 32% to 68% in the adjuvant and metastatic settings, suggest the critical need for a companion diagnostic to predict which patients are most likely to benefit from taxane therapy and which can be spared the cytotoxic effects of such therapy [3].Taxanes induce mitotic arr
%K microtubule associated protein- tau (MAP-tau)
%K metastatic breast cancer
%K taxanes
%K prognostic
%K predictive
%K quantitative analysis
%K immunohistochemistry
%U http://breast-cancer-research.com/content/13/5/R85